What is the main difference between MariTide and Tirzepatide?

Both MariTide and Tirzepatide are researched in the context of metabolic health. MariTide has Moderate evidence while Tirzepatide has High evidence.

Which has more clinical evidence, MariTide or Tirzepatide?

MariTide has 14 sources (12 human studies), rated Moderate evidence. Tirzepatide has 42 sources (38 human studies), rated High evidence.

Are MariTide and Tirzepatide FDA approved?

MariTide is not FDA-approved and remains a research compound. Tirzepatide is FDA-approved for specific indications. Only FDA-approved medications have undergone the full regulatory review process.

Can MariTide and Tirzepatide be used together?

There is no published clinical data on the safety or efficacy of using MariTide and Tirzepatide together. Without controlled human studies evaluating this combination, the safety profile is unknown. Consult a qualified healthcare provider before considering any peptide regimen.

Maritide vs Tirzepatide: Which Has Better Evidence?

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

Overview

Maritide (AMG 133) is Amgen’s investigational dual GLP-1/GIP receptor agonist being developed for obesity, while tirzepatide (Mounjaro, Zepbound) is an FDA-approved dual agonist from Eli Lilly for type 2 diabetes and obesity.

Key distinction: Tirzepatide is an approved medication with extensive clinical data; maritide is still in clinical development with promising but limited data.

Key Facts

Aspect	Maritide (AMG 133)	Tirzepatide
Developer	Amgen	Eli Lilly
Class	GLP-1 agonist / GIP antagonist	GLP-1/GIP dual agonist
FDA Status	Investigational (Phase 2)	Approved (2022/2023)
Brand Names	N/A	Mounjaro, Zepbound

Mechanism Comparison

Aspect	Maritide	Tirzepatide
GLP-1 Receptor	Agonist	Agonist
GIP Receptor	Antagonist	Agonist
Approach	Blocks GIP while activating GLP-1	Activates both receptors
Half-life	~21+ days	~5 days

How They Work

Maritide:

GLP-1 receptor agonist component stimulates insulin secretion and satiety
GIP receptor antagonist component blocks GIP action
Rationale: Some research suggests GIP antagonism may enhance weight loss
Long half-life allows monthly dosing
Bispecific antibody-peptide fusion technology

Tirzepatide:

Dual agonist at both GLP-1 and GIP receptors
GIP activation enhances GLP-1 effects on metabolism
Single peptide molecule with dual receptor activity
Weekly dosing maintains consistent drug levels

Evidence Quality

Maritide Research

Trial Phase	Status	Key Findings
Phase 1	Completed	Demonstrated GLP-1 agonism + GIP antagonism
Phase 2 (Obesity)	Ongoing/Reported	Significant weight loss (up to ~15-17% reported)
Phase 3	Not yet initiated	Pending
Long-term data	Not available	—

Current evidence:

Limited to Phase 1/2 data
Promising weight loss results in early trials
Monthly dosing demonstrated feasibility
Full safety profile not yet established

Tirzepatide Research

Trial Phase	Status	Key Findings
SURPASS (T2D)	Completed	1.5-2.4% A1c reduction
SURMOUNT (Obesity)	Completed	15-22% weight loss
Phase 3	Extensive	Multiple completed trials
Real-world data	Growing	Post-marketing experience

Established evidence:

Largest RCTs in obesity showed ~20%+ weight loss
Superior efficacy to semaglutide in head-to-head trials
Approved for both type 2 diabetes and chronic weight management
Well-characterized safety profile from large trials

Evidence Strength Comparison

Factor	Maritide	Tirzepatide
Peer-reviewed studies	Limited	Extensive
Phase 3 trials	None completed	Multiple completed
Total patients studied	Hundreds	Thousands
Long-term safety	Unknown	Established (2+ years)
Overall quality	Low (early development)	High

Efficacy Comparison

Weight Loss

Metric	Maritide	Tirzepatide
Phase 2 weight loss	~14-17% (reported)	15-22%
Phase 3 weight loss	Pending	15-22%
Maintenance data	Not available	Available
Certainty	Low	High

Glycemic Control

Metric	Maritide	Tirzepatide
A1c reduction	Limited data	1.5-2.4%
Diabetes indication	Not pursued	FDA approved
Data quality	Early	Robust

Side Effects

Maritide (Limited Phase 2 Data)

Side Effect	Reported	Notes
Nausea	Yes	Common with GLP-1 class
Vomiting	Yes	Common with GLP-1 class
Diarrhea	Yes	GI effects expected
Injection site reactions	Yes	—

Tirzepatide (Established Profile)

Side Effect	Incidence	Management
Nausea	12-33%	Dose titration helps
Diarrhea	12-21%	Usually transient
Vomiting	5-12%	Dose-dependent
Constipation	6-12%	Common
Injection site reactions	2-7%	Mild, transient

Safety Considerations

Maritide:

Full safety profile unknown
Long-acting nature could prolong adverse effects
Monthly dosing may be advantage if well-tolerated
GIP antagonism effects long-term unknown

Tirzepatide:

GI side effects most common, usually improve with time
Rare pancreatitis risk (class warning)
Thyroid C-cell tumor warning (rodent findings)
Not for patients with MEN2 or medullary thyroid cancer history

Regulatory Status

Aspect	Maritide	Tirzepatide
FDA (T2D)	Not approved	Approved (Mounjaro, 2022)
FDA (Obesity)	Not approved	Approved (Zepbound, 2023)
EMA	Not approved	Approved
Development stage	Phase 2	Post-marketing
Availability	Clinical trials only	Prescription available

Cost Considerations

Factor	Maritide	Tirzepatide
Current cost	N/A (investigational)	~$1,000+/month retail
Insurance coverage	N/A	Variable, often limited
Projected cost	Unknown	—

Who Might Consider Each

Tirzepatide May Be Appropriate For:

Type 2 diabetes requiring additional glycemic control
Chronic weight management with BMI criteria
Those who want established, approved treatment
Patients who can manage weekly injections

Maritide (If Approved) Could Be For:

Patients preferring less frequent injections
Those who have tried other GLP-1 agents
Obesity treatment (primary focus)
Must await regulatory approval

Summary

Factor	Maritide	Tirzepatide
Evidence quality	Low (Phase 2)	High (Phase 3, approved)
Efficacy (weight loss)	Promising (~15-17%)	Established (15-22%)
Mechanism	GLP-1 agonist / GIP antagonist	GLP-1/GIP dual agonist
Availability	Investigational	Prescription
Safety profile	Incomplete	Well-characterized

Key takeaway: Tirzepatide is an approved medication with extensive data supporting its use. Maritide shows promise with monthly dosing and a novel mechanism but remains investigational. Patients should only access maritide through clinical trials until approval.

This comparison is for educational purposes only. Maritide is not FDA-approved; tirzepatide requires a prescription. Consult a healthcare provider for treatment decisions.

Maritide vs Tirzepatide

MariTide

Tirzepatide